Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

v2.4.0.8
Commitments and Contingencies (Details Textual) (USD $)
12 Months Ended
Jun. 30, 2013
Sep. 06, 2013
Commitments and Contingencies     
Long Term Purchase Commitment Total Payments 10,000,000  
Long Term Purchase Commitment Payment Frequency semi-annual  
Long Term Purchase Commitment Payment Amount 1,000,000  
Long-term Purchase Commitment, Time Period 15 years  
Long-term Purchase Commitment, Amount 200,000  
Fraunhofer [Member]
   
Commitments and Contingencies   $ 3,000,000
Long-term Purchase Commitment, Description The TTA requires: 1) the Company, in consideration of Fraunhofer’s performance obligations, to make non-refundable payments to Fraunhofer totaling $10 million in semi-annual installments of $1 million commencing in November 2009; and 2) Fraunhofer to expend at least equal amounts during the same timeframe for research and development services related to the commercialization of the Technology.   Additionally, under the terms of the TTA and for a period of 15 years: 1) the Company shall pay Fraunhofer a defined percentage (per the agreement) of all receipts derived by the Company from sales of products produced utilizing the Technology and a defined percentage (per the agreement) of all receipts derived by the Company from licensing the Technology to third parties, with an overall minimum annual payment of $200,000 commencing on December 31, 2010; and 2) Fraunhofer shall pay the Company a defined percentage (per the agreement) of all receipts from sales, licensing, or commercialization of the Technology in developing countries as defined in the agreement. All new intellectual property invented by Fraunhofer during the period of the TTA is owned by and is required to be transferred to iBio.